Format

Send to

Choose Destination
J Invest Dermatol. 2015 Jan;135(1):31-38. doi: 10.1038/jid.2014.295. Epub 2014 Aug 14.

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes.

Author information

1
Department of Dermatology, Faculty of Medicine, Hôpital Edouard Herriot, University of Lyon, Lyon, France. Electronic address: denis.jullien@chu-lyon.fr.
2
Clinic for Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.
3
St. John's Institute of Dermatology, King's College London School of Medicine, London, UK.

Abstract

A potential limitation in the use of biologic drugs used to treat psoriasis is the development of anti-drug antibodies (ADAs). Many factors contribute to this unwanted immune response, from the product itself, to its mode of administration, the underlying disease, and patient characteristics. ADAs may decrease the efficacy of biologic drugs by neutralizing them or modifying their clearance and may account for hypersensitivity reactions. This article reviews the scientific basis of immunogenicity and the mechanisms by which it affects clinical outcomes. It also considers testing for immunogenicity and how biologic therapy of psoriasis may be tailored on the basis of immunogenicity.

PMID:
25120005
DOI:
10.1038/jid.2014.295
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center